针对癌症治疗的化学因受体CXCR4进行向
Ariana Rueda1,2,3, Naroa Serna2,4, Ramon Mangues5,6,7
1Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77 - 79, Barcelona, 08041, Spain.
4型C-X-C化学因子受体 (CXCR4) 是癌症的一个关键生物标志物,驱动瘤进展和转移. 针对CXCR4的生物技术创新显示出改变癌症治疗和诊断的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物技术是生物技术.
背景情况:
- 在20多种癌症类型中,C-X-C化学因子受体4型 (CXCR4) 过度表达,与攻击性和不良预后相关.
- CXCR4在瘤进展,转移和干细胞表型中发挥着关键作用.
- 最初被确定为HIV共受体,CXCR4现在是癌症治疗的重要目标.
研究的目的:
- 审查针对CXCR4.4的癌症治疗和诊断的生物技术创新.
- 讨论涉及CXCR4抑制和向药物递送的新兴治疗策略.
主要方法:
- 对向CXCR4的配体和对抗剂的文献综述.
- 分析最近在癌症治疗和诊断方面的生物技术进步.
- 探索新的治疗策略,包括小分子抑制剂和纳米载体.
主要成果:
- 已经开发出许多CXCR4向剂 (小分子,,生物制剂).
- 生物技术的进步为未来的癌症治疗提供了巨大的潜力.
- 像纳米载体这样的有针对性的输送系统,对精确纳米医学有很大的希望.
结论:
- CXCR4是一个关键的分子标,在瘤学中具有显著的治疗和诊断潜力.
- 新兴的策略集中在阻止CXCR4信号传递和向向癌症干细胞的药物输送上.
- 生物技术驱动的创新有望彻底改变癌症治疗模式.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
08:22Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
Published on: May 31, 2020
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotaxis and Direction of Cell Migration
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
